Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study.
F. de Rosa
No relevant relationships to disclose
V. Agostini
No relevant relationships to disclose
S. Di Girolamo
No relevant relationships to disclose
P. Andreone
No relevant relationships to disclose
F. Trevisani
No relevant relationships to disclose
L. Bolondi
No relevant relationships to disclose
A. D. Pinna
No relevant relationships to disclose
C. Serra
No relevant relationships to disclose
R. Golfieri
No relevant relationships to disclose
G. Biasco
No relevant relationships to disclose
G. Brandi
No relevant relationships to disclose